Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1- nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells

Biochemical Pharmacology

Volumn 84, Issue 1, 2012, Pages 30-42

  Wiśniewska, Anita ^a   Niemira, Magdalena ^a   Jagiełło, Karolina ^a   Potega, Agnieszka ^a   Świst, Małgorzata ^b   Henderson, Colin ^c   Skwarska, Anna ^a   Augustin, Ewa ^a   Konopa, Jerzy ^a   Mazerska, Zofia ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

1 Nitroacridines; Antitumour agents; C 1748; Capridine ; Hypoxia; Metabolism

Indexed keywords

(2' 9 HYDROXYETHYLAMINO) 1 NITROACRIDINE; 1 AMINOACRIDINONE; 4 METHYL 9 HYDROXYETHYLAMINO 1 NITROACRIDINE; AMINO 9 HYDROXYETHYLAMINOACRIDINE; ANTINEOPLASTIC AGENT; C 1748; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEPG2; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINOACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CELL CULTURE TECHNIQUES; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITRACRINE; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860675377     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.03.013     Document Type: Article

References (35)

1. Konopa J, Wysocka-Skrzela B, Tiwari RK. 9-Alkilamino-1-nitroacridine derivatives, European patent, 01910914.9-2101-US0105199 (1981), American patent, 6.589.961 B2.
2. E. Augustin, A. Moś-Rompa, D. Nowak-Ziatyk, and J. Konopa Antitumor 1-nitroacridine derivative C-1748, induces apoptosis, necrosis or senescence in human colon carcinoma HCT8 and HT29 cells Biochem Pharmacol 79 2010 1231 1241
3. Y. Chen, B.T. Ashok, V.P.S. Garikapaty, A. Szostek, B. Wysocka-Skrzela, and D. Banergie Preclinical studies of 1-nitroacridines derivatives: effective anti-tumor agents for prostate cells Proc Am Assoc Cancer Res 45 2002 390 abstract
4. K. Tadi, Y. Chen, B.T. Ashok, D. Banerjee, J. Konopa, and R.K. Tiwari Induction of androgen receptor by a novel nitroacridine, C-1748: implication for its role as a chemotherapeutic agent in hormone independent prostate cancer Proc Am Assoc Cancer Res 46 2005 5885 abstract
5. K. Tadi, B.T. Ashok, Y.T. Chen, D. Banerjee, B. Wysocka-Skrzela, and J. Konopa Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer Cancer Biol 6 2007 1632 1637
6. R. Narayanan, P. Tiwari, D. Inoa, and B.T. Ashok Comparative analysis of mutagenic potency of 1-nitro-acridine derivatives Life Sci 77 2005 2312 2323
7. WHO Chronicle vol. 30 (Suppl. 3) 1976 World Health Organisation Geneva p. 11
8. J. Konopa, J. Pawlak, and K. Pawlak The mode of action of cytotoxic and antitumor 1-nitroacridine. III: in vivo interstrand cross-linking of DNA mammalian or bacterial cells by 1-nitroacridines Chem Biol Interact 43 1983 175 197
9. J. Woynarowski, H. McNamee, L. Szmigiero, T.A. Beerman, and J. Konopa Induction of DNA-protein crosslinks by antitumor 1-nitro-9-aminoacridines in L1210 leukemia cells Biochem Pharmacol 38 1989 4095 4101
10. K. Pawlak, J.W. Pawlak, and J. Konopa Cytotoxic and antitumor activity of 1-nitroacridines as an after effect of their interstrand DNA cross-linking Cancer Res 44 1984 4289 4296
11. W.R. Wilson, W.A. Denny, S.J. Twigden, B.C. Baguley, and J.C. Probert Selective toxicity of Nitracrine to hypoxic mammalian cells Br J Cancer 49 1984 215 223
12. W.R. Wilson, W.A. Denny, G.M. Steward, A. Fenn, and J.C. Probert Reductive metabolism and hypoxia selective metabolism of Nitracrine Int J Radiat Oncol Biol Phys 12 1986 1235 1238
13. W.R. Wilson, R.F. Anderson, and W.A. Denny Hypoxia-selective antitumor agents. 1: relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of Nitracrine J Med Chem 32 1989 23 30
14. J. Chodkowski, and W. Kiwak Polarographic investigations on acridine derivatives. Part III: mononitro derivatives of 9- dimethylaminoalkylaminoacridines Rocz Chem 47 1973 157 170
15. C.J. O'Connor, D.J. McLennan, B.M. Sutton, W.A. Denny, and W.R. Wilson Effect of reduction potential on the rate of reduction of nitroacridines by xanthine oxidase and by dihydroflavin mononucleotide J Chem Soc Perkin Trans 2 1991 951 954
16. M. Gniazdowski, and L. Szmigiero Nitracrine and its congeners: an overview Gen Pharmacol 26 1995 473 481
17. K. Gorlewska, Z. Mazerska, P. Sowiński, and J. Konopa Products of metabolic activation of the antitumor drug Ledakrin (Nitracrine) in vitro Chem Res Toxicol 14 2001 1 10
18. B.T. Ashok, K. Tadi, D. Banerjee, J. Konopa, M. Iatropoulos, and R.K. Tiwari Pre-clinical toxicology and pathology of 9-(2′-hydroxyethylamino)- 4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in male Beagle dogs Life Sci 79 2006 1334 1342
19. B.T. Ashok, K. Tadi, V.P.S. Garikapaty, Y. Chen, Q. Huang, and D. Banerjee Preclinical toxicological examination of a putative prostate cancer-specific 4-methyl-1-nitroacridine derivative in rodents Anti Cancer Drugs 18 2007 87 94
20. ®, against some ascitic experimental tumors Arzneimittel Forschung 40 1990 472 477
21. C.J. Henderson, D.M.E. Otto, D. Carrie, M.A. Magnuson, A.W. McLaren, and I. Rosewell Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase J Biol Chem 278 2003 13480 13486
22. D.E. Feierman, Z. Melnikov, and J. Zhang The paradoxical effect of acetaminophen on CYP3A4 activity and content in transfected HepG2 cells Arch Biochem Biophys 398 2002 109 117
23. A. Bartoszek, and J. Konopa 32P-post-labeling analysis of DNA adduct formation by antitumor drug Nitracrine (Ledakrin) and other nitroacridines in different biological systems Biochem Pharmacol 38 1989 1301 1312
24. W.R. Wilson, K.O. Hicks, S.M. Pullen, D.M. Ferry, N.A. Helsy, and A.W. Patterson Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards Radiat Res 167 2007 625 636
25. N.A. Helsby, M.A. Goldthorpe, M.H.Y. Tang, G.J. Atwell, E.A. Smith, and W.R. Wilson Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide-2-mustard prodrugs Drug Metab Dispos 36 2008 353 360
26. M. Schacker, H. Forth, J. Schluter, and R. Kahl Oxidation of Tris to one-carbon compounds in a radical-producing model system, in microsomes, in hepatocytes and in rats Free Radic Res Commun 11 1991 339 347
27. D.J. Taatjes, G. Gaudiano, and T.H. Koch Production of formaldehyde and DNA-Adrimycin or DNA-Daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron or glutathione/iron Chem Res Toxicol 10 1997 953 961
28. M.T. Konieczny, and J. Konopa Nucleophilic substitution of hydrogen atom in 1-nitroacridine derivatives. Part II: mechanism of 1-nitro-9- piperidinoacridine reaction with piperidine. Intramolecular transfer of oxygen atom from the nitro to acridine ring Pol J Chem 54 1980 2233 2237
29. C. Fradette, and P. du Souich Effect of hypoxia on cytochrome P450 activity and expression Curr Drug Metab 5 2004 257 271
30. C. Legendre, T. Hori, P. Loyer, C. Aninat, S. Ishida, and D. Glaise Drug-metabolizing enzymes are down regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1α involvement in CYP3A4 repression Eur J Cancer 45 2009 2882 2892
31. W.R. Wilson, L.H. Thompson, R.F. Anderson, and W.A. Denny Hypoxia-selective antitumor agents. 2: electronic effects of 4-substituents on the mechanism of cytotoxicity and metabolic stability of Nitracrine derivatives J Med Chem 32 1989 31 38
32. J.M. Brown, and W.R. Wilson Exploiting tumour hypoxia in cancer treatment Nat Rev Cancer 4 2004 437 447
33. N. Rohwer, and T. Cramer Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways Drug Resist Updat 14 2011 191 201
34. J.M. Heddeleston, Z. Li, J.D. Lathia, S. Bao, A.B. Hjelmeland, and J.N. Rich Hypoxia inducible factors in cancer stem cells Br J Cancer 102 2010 789 795
35. J. Paradziej-Lukowicz, A. Skwarska, G. Peszynska-Sularz, A. Brillowska-Dabrowska, and J. Konopa Anticancer imidazoacridinone C-1311 inhibits hypoxia inducible factor-1 alpha (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis Cancer Biol Ther 12 2011 586 597